|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TARSL2 |
Gene summary for TARSL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TARSL2 | Gene ID | 123283 |
| Gene name | threonyl-tRNA synthetase 3 | |
| Gene Alias | TARSL2 | |
| Cytomap | 15q26.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A2RTX5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 123283 | TARSL2 | LZE4T | Human | Esophagus | ESCC | 1.75e-03 | 2.23e-01 | 0.0811 |
| 123283 | TARSL2 | LZE20T | Human | Esophagus | ESCC | 1.12e-02 | 1.60e-01 | 0.0662 |
| 123283 | TARSL2 | LZE21T | Human | Esophagus | ESCC | 3.94e-03 | 1.83e-01 | 0.0655 |
| 123283 | TARSL2 | P1T-E | Human | Esophagus | ESCC | 1.23e-11 | 6.22e-01 | 0.0875 |
| 123283 | TARSL2 | P2T-E | Human | Esophagus | ESCC | 3.56e-21 | 2.43e-01 | 0.1177 |
| 123283 | TARSL2 | P4T-E | Human | Esophagus | ESCC | 2.29e-16 | 3.95e-01 | 0.1323 |
| 123283 | TARSL2 | P5T-E | Human | Esophagus | ESCC | 1.63e-58 | 9.95e-01 | 0.1327 |
| 123283 | TARSL2 | P8T-E | Human | Esophagus | ESCC | 2.76e-09 | 1.93e-01 | 0.0889 |
| 123283 | TARSL2 | P9T-E | Human | Esophagus | ESCC | 1.23e-21 | 5.74e-01 | 0.1131 |
| 123283 | TARSL2 | P10T-E | Human | Esophagus | ESCC | 5.56e-17 | 2.96e-01 | 0.116 |
| 123283 | TARSL2 | P11T-E | Human | Esophagus | ESCC | 1.42e-10 | 5.14e-01 | 0.1426 |
| 123283 | TARSL2 | P12T-E | Human | Esophagus | ESCC | 3.79e-26 | 5.58e-01 | 0.1122 |
| 123283 | TARSL2 | P15T-E | Human | Esophagus | ESCC | 2.70e-17 | 3.67e-01 | 0.1149 |
| 123283 | TARSL2 | P16T-E | Human | Esophagus | ESCC | 2.01e-16 | 3.31e-01 | 0.1153 |
| 123283 | TARSL2 | P17T-E | Human | Esophagus | ESCC | 3.74e-03 | 2.22e-01 | 0.1278 |
| 123283 | TARSL2 | P19T-E | Human | Esophagus | ESCC | 1.20e-09 | 7.65e-01 | 0.1662 |
| 123283 | TARSL2 | P20T-E | Human | Esophagus | ESCC | 3.47e-17 | 2.60e-01 | 0.1124 |
| 123283 | TARSL2 | P21T-E | Human | Esophagus | ESCC | 3.00e-16 | 2.89e-01 | 0.1617 |
| 123283 | TARSL2 | P22T-E | Human | Esophagus | ESCC | 1.30e-13 | 2.44e-01 | 0.1236 |
| 123283 | TARSL2 | P23T-E | Human | Esophagus | ESCC | 1.97e-24 | 6.36e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TARSL2 | SNV | Missense_Mutation | c.2395G>A | p.Glu799Lys | p.E799K | A2RTX5 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TARSL2 | SNV | Missense_Mutation | c.1819G>A | p.Glu607Lys | p.E607K | A2RTX5 | protein_coding | tolerated(0.69) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TARSL2 | SNV | Missense_Mutation | c.319N>A | p.Asp107Asn | p.D107N | A2RTX5 | protein_coding | tolerated(0.26) | benign(0.015) | TCGA-BH-A201-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TARSL2 | SNV | Missense_Mutation | rs145946175 | c.1165G>A | p.Asp389Asn | p.D389N | A2RTX5 | protein_coding | tolerated(0.05) | benign(0) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TARSL2 | SNV | Missense_Mutation | novel | c.1001G>A | p.Gly334Asp | p.G334D | A2RTX5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TARSL2 | SNV | Missense_Mutation | novel | c.2150N>G | p.Ser717Cys | p.S717C | A2RTX5 | protein_coding | tolerated(0.51) | benign(0.012) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TARSL2 | SNV | Missense_Mutation | novel | c.2284N>C | p.Asp762His | p.D762H | A2RTX5 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TARSL2 | SNV | Missense_Mutation | c.2242N>G | p.Gln748Glu | p.Q748E | A2RTX5 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TARSL2 | SNV | Missense_Mutation | c.2180C>T | p.Ala727Val | p.A727V | A2RTX5 | protein_coding | tolerated(0.55) | benign(0.023) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TARSL2 | SNV | Missense_Mutation | c.1070T>G | p.Phe357Cys | p.F357C | A2RTX5 | protein_coding | deleterious(0.02) | possibly_damaging(0.852) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |